Niagen Bioscience (NAGE) Cash & Equivalents (2015 - 2026)

Niagen Bioscience (NAGE) has 12 years of Cash & Equivalents data on file, last reported at $66.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 19.66% year-over-year to $66.5 million in Q1 2026; TTM through Mar 2026 was $66.5 million, a 19.66% increase from a year earlier, with the FY2025 full-year figure at $64.8 million, up 45.07% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $66.5 million, up from $64.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NAGE reached as high as $66.5 million in Q1 2026 and fell as low as $13.3 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $36.4 million across 5 years, with a median of $27.6 million in 2024.
• Across the five-year window, Cash & Equivalents sank 59.94% in 2022 and surged 116.87% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $20.4 million in 2022, then surged by 33.68% to $27.3 million in 2023, then soared by 63.44% to $44.7 million in 2024, then soared by 45.07% to $64.8 million in 2025, then gained by 2.72% to $66.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $66.5 million in Q1 2026, $64.8 million in Q4 2025, and $64.3 million in Q3 2025.